Drugs / Chronocort
Chronocort
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03343327 | Feb → Apr 2018 | adrenocortical insufficiency | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT03019614 | Mar → Apr 2010 | congenital adrenal hyperplasia | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00519818 | Aug 2007 → May 2009 | classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | Neurocrine UK Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-05-08 | Immedica Pharma AB | Regulatory Efmody® (modified-release hydrocortisone) receives MHRA approval for adrenal insufficiency in the UK immedica.com ↗ |
| 2026-04-07 | Immedica Pharma AB | Regulatory Efmody® (modified-release hydrocortisone) granted extension of indication for adrenal insufficiency immedica.com ↗
Immedica Pharma AB is pleased to announce that the European Commission (EC) has granted extension of indication for Efmody® (modified-release hydrocortisone) to include treatment of adrenal insufficiency (AI) in adolescents aged 12 years and over and adults. |
| 2023-06-15 | Neurocrine Biosciences | Results Diurnal Ltd., a Neurocrine Biosciences Company, Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Patients with Congenital Adrenal Hyperplasia at ENDO 2023 gcs-web.com ↗
The number of patients achieving lower androgen levels while receiving ≤25 mg of hydrocortisone per day increased significantly, with 48 percent of the subjects achieving 17-OHP levels <36 nmol/L compared with 31 percent at baseline. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-08 | Immedica Pharma AB | Efmody® (modified-release hydrocortisone) receives MHRA approval for adrenal insufficiency in the UK immedica.com ↗ |
| 2026-04-07 | Immedica Pharma AB | Efmody® (modified-release hydrocortisone) granted extension of indication for adrenal insufficiency immedica.com ↗ |
| 2023-06-15 | Neurocrine Biosciences | Diurnal Ltd., a Neurocrine Biosciences Company, Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Patients with Congenital Adrenal Hyperplasia at ENDO 2023 gcs-web.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Chronocort | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03019614 ↗ |
| Known as | hydrocortisone | “This study will test a new, extended release form of hydrocortisone called Chronocort in patients with congenital adrenal hyperplasia (CAH).” NCT00519818 ↗ |
| Known as | Hydrocortisone modified release tablet treatment | “Hydrocortisone modified release tablet treatment” NCT00519818 ↗ |
| Action | Restore | “This new medical strategy, physiologic cortisol replacement, offers the prospect of an improved outcome of treatment.” NCT00519818 ↗ |
| Route | Oral | “Chronocort® 5mg given at night (\~ 23:00h) as one 5mg capsule” NCT03019614 ↗ |